AN2 Therapeutics Inc (ANTX)
2.32
+0.04
(+1.75%)
USD |
NASDAQ |
Apr 26, 16:00
2.32
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Cash from Operations (TTM): -53.29M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -53.29M |
| September 30, 2023 | -43.86M |
| June 30, 2023 | -41.54M |
| March 31, 2023 | -38.32M |
| December 31, 2022 | -33.46M |
| Date | Value |
|---|---|
| September 30, 2022 | -34.82M |
| June 30, 2022 | -30.02M |
| March 31, 2022 | -25.68M |
| December 31, 2021 | -20.48M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-53.29M
Minimum
Dec 2023
-20.48M
Maximum
Dec 2021
-35.72M
Average
-34.82M
Median
Sep 2022
Cash from Operations (TTM) Benchmarks
| Gilead Sciences Inc | 8.006B |
| QuidelOrtho Corp | 280.20M |
| CymaBay Therapeutics Inc (DELISTED) | -72.53M |
| Insmed Inc | -536.25M |
| Revance Therapeutics Inc | -216.58M |